What is Nucleai?
Nucleai operates at the intersection of advanced computational biology and clinical oncology. The company provides a sophisticated AI-powered platform designed to extract actionable insights from complex tissue datasets, thereby enhancing the efficacy of clinical trials and refining patient care protocols. By collaborating with major pharmaceutical entities, Nucleai facilitates the licensing of its research infrastructure, enabling partners to streamline internal biomarker discovery projects. This market position as a critical technology enabler allows the firm to bridge the gap between raw biological data and clinical application, effectively reducing the time and cost associated with drug development cycles in the oncology space.
How much funding has Nucleai raised?
Nucleai has raised a total of $53.5M across 3 funding rounds:
Series A
$6.5M
Series B
$33M
Other Financing Round
$14M
Series A (2020): $6.5M with participation from Debiopharm Group companies, Grove Ventures Capital, and Vertex Ventures
Series B (2022): $33M led by Sanofi Ventures and Section 32
Other Financing Round (2024): $14M supported by Merck Ventures
Key Investors in Nucleai
Vertex Ventures
Vertex Ventures US is an early-stage venture capital firm that supports founders creating a smarter digital economy through B2B software, leveraging their experience as former founders and operators.
Sanofi Ventures
Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies with innovative ideas and transformative technologies of strategic interest.
Section 32
S32 is a venture capital firm founded by Bill Maris that focuses on investing in cutting-edge technology and supporting visionary entrepreneurs at the forefront of technological advancement.
What's next for Nucleai?
With the successful closure of this recent financing round, Nucleai is well-positioned to scale its operational footprint and deepen its collaborative efforts with global pharmaceutical leaders. The strategic focus will likely shift toward expanding the utility of its AI platform across broader therapeutic areas and enhancing the predictive capabilities of its biomarker discovery engine. As the company matures, the emphasis will remain on solidifying its role as an indispensable partner in the pharmaceutical value chain, potentially exploring new avenues for commercializing its research insights and driving the next generation of precision medicine initiatives.
See full Nucleai company page
